EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity

Keifer G Kurtz iD, Irina Lebedeva, Stephanie A Pierre, David Andrew, Yu-Rou Liao, Daisy Ambriz, Olivia Vergnolle iD, Leyi Shen, Elizabeth Nyakatura, Manuel Baca, David A Scheinberg iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0321169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Keifer G Kurtz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Program, Sloan Kettering Institute, New York, United States of America. Hauptthemen laut MEDLINE: Receptors, Immunologic, Macrophages, Antibodies, Monoclonal, Antigens, Differentiation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Greenberg Medical Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several T cell immune checkpoint blockade therapies have shown initial successes in multiple cancers. However, significant issues remain, including tumor relapse, severe toxicities, and a lack of efficacy in most patients. SIRPα, commonly known as the “do not eat me signal”, is a monocyte checkpoint cell surface protein. Agents that block the interaction of CD47 with SIRPα have recently shown clinical success in combination with monoclonal antibody therapy to potentiate macrophage phagocytosis of tumors. However, significant toxicities and logistical issues are associated with CD47-targeted agents due to the expression of CD47 on all human cells. In contrast, SIRPα has expression limited to myelomonocytic cells, meaning highly specific SIRPα blocking agents might reduce these toxicities and avoid the target antigen sink. Herein, we generated a high affinity and highly specific SIRPα-targeting monoclonal antibody, F05, that has enhanced SIRPα binding and reduced SIRPβ and SIRPγ binding capacity when compared to other available SIRPα antibodies. Furthermore, we show F05 reprograms immunosuppressive macrophages toward a phagocytic profile in vitro . F05 demonstrated efficacy in solid tumor animal models, providing a rationale for further development of the antibody.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicMacrophagesAntibodies, MonoclonalAntigens, DifferentiationAntineoplastic Agents, ImmunologicalNeoplasmsHumansAnimalsMiceCD47 AntigenPhagocytosisCell Line, TumorFemale

Substanzen

Receptors, ImmunologicSIRPA protein, humanCD47 AntigenAntibodies, MonoclonalAntigens, DifferentiationCD47 protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Molecular Pharmacology Program, Sloan Kettering Institute, New York, United States of America.
  • Pharmacology Program, Weill Cornell Medicine, New York, United States of America.
  • Tri-Institutional Therapeutics Discovery Institute, Weill Cornell Medicine, New York, United States of America.
  • Tri-Institutional MD-PhD Program, Weill Cornell Medicine, New York, United States of America.
  • Department of Medicine, Memorial Hospital, New York, United States of America.

ORCID-Profile: Keifer G Kurtz, Olivia Vergnolle, David A Scheinberg

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • Greenberg Medical Research Institute
  • Emerson Collective

Zitieren

APA

Kurtz, K. G., Lebedeva, I., Pierre, S. A., Andrew, D., Liao, Y. R., Ambriz, D., Vergnolle, O., Shen, L., Nyakatura, E., Baca, M., & Scheinberg, D. A. (2025). A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. PLOS One. https://doi.org/10.1371/journal.pone.0321169

Vancouver

Kurtz KG, Lebedeva I, Pierre SA, Andrew D, Liao YR, Ambriz D, et al. A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity. PLOS One. 2025. doi:10.1371/journal.pone.0321169

BibTeX
@article{Kurtz2025,
  author = {Kurtz, Keifer G and Lebedeva, Irina and Pierre, Stephanie A and Andrew, David and Liao, Yu-Rou and Ambriz, Daisy and Vergnolle, Olivia and Shen, Leyi and Nyakatura, Elizabeth and Baca, Manuel and Scheinberg, David A},
  title = {A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0321169}
}
Kostenlos starten →